BioNTech's T-Pam Data Ignites Oncology Strategy as Financial Transition Looms

BioNTech's BNT323 drug shows 48% response in endometrial cancer trial, validating its oncology pivot. Analysts raise targets as company plans FDA submission.

A near 48 percent response rate in a difficult-to-treat cancer has sent a jolt of optimism through BioNTech's stock, providing crucial validation for its strategic pivot beyond COVID-19 vaccines. The company's antibody-drug conjugate candidate, trastuzumab pamirtecan (BNT323/DB-1303), demonstrated compelling efficacy in a Phase 2 trial for HER2-positive endometrial cancer, sharply outperforming the roughly 15 percent rate typical of chemotherapy. This clinical success is prompting analysts to reaffirm their bullish stance on the German biotech's long-term oncology ambitions, even as it navigates a significant near-term revenue decline.

Presented at the Society of Gynecologic Oncology's annual congress, the data from 145 patients showed a confirmed objective response rate of 47.9 percent and a median progression-free survival of 8.1 months, compared to approximately four months for standard chemo. In patients with the highest level of HER2 expression, the response rate soared to 73.1 percent. The safety profile was deemed manageable, with efficacy consistent across all HER2 expression levels and regardless of prior checkpoint inhibitor therapy.

Wall Street responded promptly. Berenberg Bank reiterated its "Buy" rating with a $155 price target. Morgan Stanley raised its target slightly to $126 from $125, maintaining an "Overweight" rating. BofA Securities increased its target to $130 from $128, also with a "Buy" recommendation. The average analyst price target now stands at $133.13, with 13 out of 18 covering analysts recommending purchase. BofA analysts noted that while the specific endometrial cancer market is modest—valuing it at around $3 per share in their target—the strategic value is paramount. A successful FDA approval would grant BioNTech its first proprietary oncology commercial infrastructure, a critical platform for future, larger pipeline programs.

The partnership with DualityBio is moving swiftly, planning to submit a Biologics License Application to the U.S. FDA later this year, pending agency feedback. A global confirmatory Phase 3 study, dubbed Fern-EC-01, is already underway, pitting the drug against chemotherapy.

This clinical momentum arrives against a backdrop of financial transition. For the full year 2026, BioNTech anticipates a revenue decline of approximately 25 percent to between €2.0 and €2.3 billion, following a net loss of €1.14 billion in fiscal 2025. However, the company is well-capitalized for its strategic shift, sitting on a liquidity reserve of about €17.2 billion. The oncology pipeline is set to expand significantly, with 15 Phase 3 trials expected to be active by the end of 2026 and data readouts from seven late-stage programs scheduled for the year. Commercial revenue from these new oncology assets is not expected before 2027.

Investors are now looking to two key May events for further direction. First-quarter 2026 financial results, due on May 5, will provide an early snapshot of the year's trajectory. This will be followed by the virtual Annual General Meeting on May 15. The agenda includes a proposed expansion of the Supervisory Board from six to eight members, intended to bring in specialized expertise in oncology and clinical development. Shareholders will also vote on creating new authorized capital 2026 of up to €129.5 million, equivalent to 50 percent of the current share capital.

The stock, trading at €84.25, has reflected the recent optimism with an 8 percent gain over the past week and a nearly 7 percent increase over the last 30 days. The broader trend remains cautious, however, with the share price still trading about 4 percent below its 200-day moving average of €88.15. The coming months will test whether clinical breakthroughs can steadily outweigh financial headwinds as BioNTech builds its new identity.